{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:57:32Z","timestamp":1793750252949,"version":"4.6.1"},"reference-count":265,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Dis Primers"],"DOI":"10.1038\/s41572-025-00664-9","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T08:02:47Z","timestamp":1762416167000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Alopecia areata"],"prefix":"10.1038","volume":"11","author":[{"given":"Benjamin","family":"Ungar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Renert-Yuval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ncoza C.","family":"Dlova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Jabbari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha A.","family":"Mesinkovska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Rudnicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6751-1428","authenticated-orcid":false,"given":"Rodney","family":"Sinclair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9363-324X","authenticated-orcid":false,"given":"Emma","family":"Guttman-Yassky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"664_CR1","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/jid.2013.464","volume":"134","author":"SA Mirzoyev","year":"2014","unstructured":"Mirzoyev, S. A., Schrum, A. G., Davis, M. D. P. & Torgerson, R. R. Lifetime incidence risk of alopecia areata estimated at 2.1% by Rochester Epidemiology Project, 1990-2009. J. Invest. Dermatol. 134, 1141\u20131142 (2014).","journal-title":"J. Invest. Dermatol."},{"key":"664_CR2","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1159\/000254503","volume":"131","author":"T Ikeda","year":"1965","unstructured":"Ikeda, T. A new classification of alopecia areata. Dermatologica 131, 421\u2013445 (1965).","journal-title":"Dermatologica"},{"key":"664_CR3","first-page":"397","volume":"8","author":"AC Villasante Fricke","year":"2015","unstructured":"Villasante Fricke, A. C. & Miteva, M. Epidemiology and burden of alopecia areata: a systematic review. Clin. Cosmet. Investig. Dermatol. 8, 397\u2013403 (2015).","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"664_CR4","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1001\/jamadermatol.2013.3049","volume":"149","author":"KP Huang","year":"2013","unstructured":"Huang, K. P., Mullangi, S., Guo, Y. & Qureshi, A. A. Autoimmune, atopic, and mental health comorbid conditions associated with alopecia areata in the United States. JAMA Dermatol. 149, 789\u2013794 (2013).","journal-title":"JAMA Dermatol."},{"key":"664_CR5","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.jaad.2019.06.1300","volume":"83","author":"H Lee","year":"2020","unstructured":"Lee, H. et al. Racial characteristics of alopecia areata in the United States. J. Am. Acad. Dermatol. 83, 1064\u20131070 (2020).","journal-title":"J. Am. Acad. Dermatol."},{"key":"664_CR6","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1007\/s00403-023-02548-y","volume":"315","author":"IH Moseley","year":"2023","unstructured":"Moseley, I. H. et al. Alopecia areata in underrepresented groups: preliminary analysis of the all of us research program. Arch. Dermatol. Res. 315, 1631\u20131637 (2023).","journal-title":"Arch. Dermatol. Res."},{"key":"664_CR7","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1001\/jamadermatol.2023.0016","volume":"159","author":"N Sy","year":"2023","unstructured":"Sy, N., Mastacouris, N., Strunk, A. & Garg, A. Overall and racial and ethnic subgroup prevalences of alopecia areata, alopecia totalis, and alopecia universalis. JAMA Dermatol. 159, 419\u2013423 (2023).","journal-title":"JAMA Dermatol."},{"key":"664_CR8","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1001\/jamadermatol.2023.0002","volume":"159","author":"A Mostaghimi","year":"2023","unstructured":"Mostaghimi, A. et al. Trends in prevalence and incidence of alopecia areata, alopecia totalis, and alopecia universalis among adults and children in a US employer-sponsored insured population. JAMA Dermatol. 159, 411\u2013418 (2023).","journal-title":"JAMA Dermatol."},{"key":"664_CR9","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1001\/jamadermatol.2022.0351","volume":"158","author":"PL McKenzie","year":"2022","unstructured":"McKenzie, P. L. et al. Evaluation of the prevalence and incidence of pediatric alopecia areata using electronic health record data. JAMA Dermatol. 158, 547\u2013551 (2022).","journal-title":"JAMA Dermatol."},{"key":"664_CR10","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/bjd.20628","volume":"186","author":"M Harries","year":"2022","unstructured":"Harries, M. et al. The epidemiology of alopecia areata: a population-based cohort study in UK primary care. Br. J. Dermatol. 186, 257\u2013265 (2022).","journal-title":"Br. J. Dermatol."},{"key":"664_CR11","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000510880","volume":"7","author":"TK Uzuncakmak","year":"2021","unstructured":"Uzuncakmak, T. K., Engin, B., Serdaroglu, S. & Tuzun, Y. Demographic and clinical features of 1,641 patients with alopecia areata, alopecia totalis, and alopecia universalis: a single-center retrospective study. Skin Appendage Disord. 7, 8\u201312 (2021).","journal-title":"Skin Appendage Disord."},{"key":"664_CR12","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1093\/bjd\/ljae307","volume":"191","author":"AR Thompson","year":"2024","unstructured":"Thompson, A. R. et al. Lifetime incidence and healthcare disparities in alopecia areata: a UK population-based cohort study. Br. J. Dermatol. 191, 924\u2013935 (2024).","journal-title":"Br. J. Dermatol."},{"key":"664_CR13","doi-asserted-by":"publisher","first-page":"628","DOI":"10.4065\/70.7.628","volume":"70","author":"KH Safavi","year":"1995","unstructured":"Safavi, K. H., Muller, S. A., Suman, V. J., Moshell, A. N. & Melton, L. J. 3rd. Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989. Mayo Clin. Proc. 70, 628\u2013633 (1995).","journal-title":"Mayo Clin. Proc."},{"key":"664_CR14","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/exd.14155","volume":"29","author":"M Bertolini","year":"2020","unstructured":"Bertolini, M., McElwee, K., Gilhar, A., Bulfone-Paus, S. & Paus, R. Hair follicle immune privilege and its collapse in alopecia areata. Exp. Dermatol. 29, 703\u2013725 (2020).","journal-title":"Exp. Dermatol."},{"key":"664_CR15","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1038\/jid.2012.129","volume":"132","author":"D Jagielska","year":"2012","unstructured":"Jagielska, D. et al. Follow-up study of the first genome-wide association scan in alopecia areata: IL13 and KIAA0350 as susceptibility loci supported with genome-wide significance. J. Invest. Dermatol. 132, 2192\u20132197 (2012).","journal-title":"J. Invest. Dermatol."},{"key":"664_CR16","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature09114","volume":"466","author":"L Petukhova","year":"2010","unstructured":"Petukhova, L. et al. Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature 466, 113\u2013117 (2010).","journal-title":"Nature"},{"key":"664_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094260","volume":"9","author":"M Bertolini","year":"2014","unstructured":"Bertolini, M. et al. Abnormal interactions between perifollicular mast cells and CD8+ T-cells may contribute to the pathogenesis of alopecia areata. PLoS ONE 9, e94260 (2014).","journal-title":"PLoS ONE"},{"key":"664_CR18","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/nm.3645","volume":"20","author":"L Xing","year":"2014","unstructured":"Xing, L. et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat. Med. 20, 1043\u20131049 (2014). To our knowledge, the first study to demonstrate JAK inhibition as a potential therapeutic approach for alopecia areata.","journal-title":"Nat. Med."},{"key":"664_CR19","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/j.jaci.2015.06.032","volume":"136","author":"M Suarez-Farinas","year":"2015","unstructured":"Suarez-Farinas, M. et al. Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17\/TH22 skewing. J. Allergy Clin. Immunol. 136, 1277\u20131287 (2015). To our knowledge, the first comprehensive transcriptomic profiling of alopecia areata in humans scalp samples.","journal-title":"J. Allergy Clin. Immunol."},{"key":"664_CR20","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","volume":"386","author":"B King","year":"2022","unstructured":"King, B. et al. Two phase 3 trials of baricitinib for alopecia areata. N. Engl. J. Med. 386, 1687\u20131699 (2022). The first phase III clinical trials to lead to an FDA-approved treatment for severe alopecia areata.","journal-title":"N. Engl. J. Med."},{"key":"664_CR21","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/S0140-6736(23)00222-2","volume":"401","author":"B King","year":"2023","unstructured":"King, B. et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial. Lancet 401, 1518\u20131529 (2023).","journal-title":"Lancet"},{"key":"664_CR22","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.jaad.2024.06.097","volume":"91","author":"B King","year":"2024","unstructured":"King, B. et al. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: results from the Phase 3 randomized, controlled trial (THRIVE-AA1). J. Am. Acad. Dermatol. 91, 880\u2013888 (2024).","journal-title":"J. Am. Acad. Dermatol."},{"key":"664_CR23","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jaad.2009.10.031","volume":"62","author":"A Alkhalifah","year":"2010","unstructured":"Alkhalifah, A., Alsantali, A., Wang, E., McElwee, K. J. & Shapiro, J. Alopecia areata update: part II. Treatment. J. Am. Acad. Dermatol. 62, 191\u2013202 (2010).","journal-title":"J. Am. Acad. Dermatol."},{"key":"664_CR24","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/ajd.14126","volume":"64","author":"R Sinclair","year":"2023","unstructured":"Sinclair, R. et al. Incidence and prevalence of alopecia areata in the Australian primary care setting: a retrospective analysis of electronic health record data. Australas. J. Dermatol. 64, 330\u2013338 (2023).","journal-title":"Australas. J. Dermatol."},{"key":"664_CR25","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/1346-8138.16615","volume":"50","author":"E Campos-Alberto","year":"2023","unstructured":"Campos-Alberto, E., Hirose, T., Napatalung, L. & Ohyama, M. Prevalence, comorbidities, and treatment patterns of Japanese patients with alopecia areata: a descriptive study using Japan medical data center claims database. J. Dermatol. 50, 37\u201345 (2023).","journal-title":"J. Dermatol."},{"key":"664_CR26","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.jaad.2019.08.032","volume":"82","author":"HH Lee","year":"2020","unstructured":"Lee, H. H. et al. Epidemiology of alopecia areata, ophiasis, totalis, and universalis: a systematic review and meta-analysis. J. Am. Acad. Dermatol. 82, 675\u2013682 (2020).","journal-title":"J. Am. Acad. Dermatol."},{"key":"664_CR27","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.jaad.2018.07.013","volume":"80","author":"S Lee","year":"2019","unstructured":"Lee, S., Lee, H., Lee, C. H. & Lee, W. S. Comorbidities in alopecia areata: a systematic review and meta-analysis. J. Am. Acad. Dermatol. 80, 466\u2013477.e16 (2019).","journal-title":"J. Am. Acad. Dermatol."},{"key":"664_CR28","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s40257-023-00805-4","volume":"24","author":"S Ly","year":"2023","unstructured":"Ly, S. et al. Comorbid conditions associated with alopecia areata: a systematic review and meta-analysis. Am. J. Clin. Dermatol. 24, 875\u2013893 (2023).","journal-title":"Am. J. Clin. Dermatol."},{"key":"664_CR29","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/j.jaip.2020.01.052","volume":"8","author":"K Kridin","year":"2020","unstructured":"Kridin, K., Renert-Yuval, Y., Guttman-Yassky, E. & Cohen, A. D. Alopecia areata is associated with atopic diathesis: results from a population-based study of 51,561 patients. J. Allergy Clin. Immunol. Pract. 8, 1323\u20131328.e1 (2020).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"664_CR30","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.anai.2024.03.013","volume":"132","author":"E Tsutsui","year":"2024","unstructured":"Tsutsui, E., Piontkowski, A. J., Sharma, D., Ramsey, N. & Ungar, B. Association between alopecia areata and allergic diseases: an all of US database study. Ann. Allergy Asthma Immunol. 132, 772\u2013774 (2024).","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"664_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2025.06.1578","author":"CG Bunick","year":"2025","unstructured":"Bunick, C. G. et al. The epidemiology of atopic dermatitis among adults and adolescents with alopecia areata in the United States. J. Invest. Dermatol. https:\/\/doi.org\/10.1016\/j.jid.2025.06.1578 (2025). The largest study to evaluate the risk of the most common comorbidity in alopecia areata patients, atopic dermatitis.","journal-title":"J. Invest. Dermatol."},{"key":"664_CR32","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.jaad.2010.08.032","volume":"65","author":"SY Chu","year":"2011","unstructured":"Chu, S. Y. et al. Comorbidity profiles among patients with alopecia areata: the importance of onset age, a nationwide population-based study. J. Am. Acad. Dermatol. 65, 949\u2013956 (2011).","journal-title":"J. Am. Acad. Dermatol."},{"key":"664_CR33","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1001\/jamadermatol.2019.0629","volume":"155","author":"S Lee","year":"2019","unstructured":"Lee, S., Lee, Y. B., Kim, B. J., Bae, S. & Lee, W. S. All-cause and cause-specific mortality risks associated with alopecia areata: a Korean nationwide population-based study. JAMA Dermatol. 155, 922\u2013928 (2019).","journal-title":"JAMA Dermatol."},{"key":"664_CR34","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1016\/j.jaad.2018.10.066","volume":"80","author":"S Lee","year":"2019","unstructured":"Lee, S., Lee, Y. B., Kim, B. J. & Lee, W. S. Screening of thyroid function and autoantibodies in patients with alopecia areata: a systematic review and meta-analysis. J. Am. Acad. Dermatol. 80, 1410\u20131413.e4 (2019).","journal-title":"J. Am. Acad. Dermatol."},{"key":"664_CR35","first-page":"e1341","volume":"37","author":"R O\u2019Hagan","year":"2023","unstructured":"O\u2019Hagan, R., Caldas, S. A., Correa da Rosa, J. M., Guttman-Yassky, E. & Ungar, B. Alopecia areata is associated with increased genetic risk of myocardial infarction: a Mendelian randomization study. J. Eur. Acad. Dermatol. Venereol. 37, e1341\u2013e1343 (2023).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"664_CR36","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.jaad.2023.05.023","volume":"89","author":"R O\u2019Hagan","year":"2023","unstructured":"O\u2019Hagan, R., Caldas, S. A., Correa da Rosa, J. M., Guttman-Yassky, E. & Ungar, B. The impact of atopic dermatitis on alopecia areata: a 2-sample Mendelian randomization study. J. Am. Acad. Dermatol. 89, 600\u2013602 (2023).","journal-title":"J. Am. Acad. Dermatol."},{"key":"664_CR37","doi-asserted-by":"publisher","first-page":"1309620","DOI":"10.3389\/fendo.2023.1309620","volume":"14","author":"XY Zheng","year":"2023","unstructured":"Zheng, X. Y. et al. Mendelian randomization study highlights hypothyroidism as a causal determinant of alopecia areata. Front. Endocrinol. 14, 1309620 (2023).","journal-title":"Front. Endocrinol."},{"key":"664_CR38","doi-asserted-by":"publisher","DOI":"10.1111\/srt.13844","volume":"30","author":"W Du","year":"2024","unstructured":"Du, W. et al. Genetic association between asthma and alopecia areata: a two-sample Mendelian randomization study. Skin Res. Technol. 30, e13844 (2024).","journal-title":"Skin Res. Technol."},{"key":"664_CR39","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.jad.2024.01.152","volume":"350","author":"N Yu","year":"2024","unstructured":"Yu, N. & Guo, Y. Association between alopecia areata, anxiety, and depression: Insights from a bidirectional two-sample Mendelian randomization study. J. Affect. Disord. 350, 328\u2013331 (2024).","journal-title":"J. Affect. Disord."},{"key":"664_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2022.e09184","volume":"8","author":"LN Al-Eitan","year":"2022","unstructured":"Al-Eitan, L. N. et al. Genetic predisposition of alopecia areata in Jordanians: a case-control study. Heliyon 8, e09184 (2022).","journal-title":"Heliyon"},{"key":"664_CR41","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1007\/s13555-024-01218-9","volume":"14","author":"K Kamal","year":"2024","unstructured":"Kamal, K. et al. Association between natural hair color, race, and alopecia. Dermatol. Ther. 14, 2109\u20132117 (2024).","journal-title":"Dermatol. Ther."},{"key":"664_CR42","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.jisp.2017.10.007","volume":"19","author":"JM Thompson","year":"2018","unstructured":"Thompson, J. M., Park, M. K., Qureshi, A. A. & Cho, E. Race and alopecia areata amongst US Women. J. Investig. Dermatol. Symp. Proc. 19, S47\u2013S50 (2018).","journal-title":"J. Investig. Dermatol. Symp. Proc."},{"key":"664_CR43","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1007\/s00403-023-02651-0","volume":"315","author":"JQ Jin","year":"2023","unstructured":"Jin, J. Q. et al. Ethnoracial disparities in alopecia areata clinical trials: a cross-sectional study with proposed recommendations. Arch. Dermatol. Res. 315, 2191\u20132194 (2023).","journal-title":"Arch. Dermatol. Res."},{"key":"664_CR44","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.jaad.2023.07.003","volume":"89","author":"R Elsanadi","year":"2023","unstructured":"Elsanadi, R. et al. Alopecia areata clinical trial enrollment and retention outcome factors among underrepresented ethnic and racial groups: A cross-sectional study. J. Am. Acad. Dermatol. 89, 1253\u20131256 (2023).","journal-title":"J. Am. Acad. Dermatol."},{"key":"664_CR45","doi-asserted-by":"crossref","unstructured":"Rakowska, A., Usatine, R. P., Mayo, T. T., Enechukwu, N. A. & Errichetti, E. in Clinical and Dermoscopic Atlas of Non-Neoplastic Dermatoses: Variability According to Phototypes (eds Errichetti E., Usatine R. P., Ankad B. S. & Lallas A.) 235\u2013251 (Springer, 2023).","DOI":"10.1007\/978-3-031-19688-1_18"},{"key":"664_CR46","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1111\/jdv.17079","volume":"35","author":"A Alessandrini","year":"2021","unstructured":"Alessandrini, A., Bruni, F., Piraccini, B. M. & Starace, M. Common causes of hair loss - clinical manifestations, trichoscopy and therapy. J. Eur. Acad. Dermatol. Venereol. 35, 629\u2013640 (2021).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"664_CR47","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/1346-8138.12500","volume":"41","author":"M Ise","year":"2014","unstructured":"Ise, M., Amagai, M. & Ohyama, M. Follicular microhemorrhage: a unique dermoscopic sign for the detection of coexisting trichotillomania in alopecia areata. J. Dermatol. 41, 518\u2013520 (2014).","journal-title":"J. Dermatol."},{"key":"664_CR48","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1111\/j.1365-4632.2011.05098.x","volume":"50","author":"P Summers","year":"2011","unstructured":"Summers, P., Kyei, A. & Bergfeld, W. Central centrifugal cicatricial alopecia - an approach to diagnosis and management. Int. J. Dermatol. 50, 1457\u20131464 (2011).","journal-title":"Int. J. Dermatol."},{"key":"664_CR49","doi-asserted-by":"publisher","first-page":"708","DOI":"10.36849\/JDD.9139","volume":"24","author":"J Pyles","year":"2025","unstructured":"Pyles, J., Palmer, V., Balding, E., Larrondo, J. & McMichael, A. Alopecia areata in skin of color: trichoscopic analysis in Black\/African American patients. J. Drugs Dermatol. 24, 708\u2013712 (2025).","journal-title":"J. Drugs Dermatol."},{"key":"664_CR50","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/cpt.61","volume":"97","author":"A Ramamoorthy","year":"2015","unstructured":"Ramamoorthy, A., Pacanowski, M. A., Bull, J. & Zhang, L. Racial\/ethnic differences in drug disposition and response: review of recently approved drugs. Clin. Pharmacol. Ther. 97, 263\u2013273 (2015).","journal-title":"Clin. Pharmacol. Ther."},{"key":"664_CR51","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1007\/s13555-023-00941-z","volume":"13","author":"N Mesinkovska","year":"2023","unstructured":"Mesinkovska, N. et al. The invisible impact of a visible disease: psychosocial impact of alopecia areata. Dermatol. Ther. 13, 1503\u20131515 (2023).","journal-title":"Dermatol. Ther."},{"key":"664_CR52","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1046\/j.0022-202x.2001.01583.x","volume":"117","author":"A Gilhar","year":"2001","unstructured":"Gilhar, A. et al. Melanocyte-associated T cell epitopes can function as autoantigens for transfer of alopecia areata to human scalp explants on Prkdc(scid) mice. J. Invest. Dermatol. 117, 1357\u20131362 (2001).","journal-title":"J. Invest. Dermatol."},{"key":"664_CR53","doi-asserted-by":"publisher","first-page":"5153","DOI":"10.1021\/pr100422u","volume":"9","author":"MC Leung","year":"2010","unstructured":"Leung, M. C., Sutton, C. W., Fenton, D. A. & Tobin, D. J. Trichohyalin is a potential major autoantigen in human alopecia areata. J. Proteome Res. 9, 5153\u20135163 (2010).","journal-title":"J. Proteome Res."},{"key":"664_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6966","volume":"6","author":"RC Betz","year":"2015","unstructured":"Betz, R. C. et al. Genome-wide meta-analysis in alopecia areata resolves HLA associations and reveals two new susceptibility loci. Nat. Commun. 6, 5966 (2015).","journal-title":"Nat. Commun."},{"key":"664_CR55","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1056\/NEJM199908123410706","volume":"341","author":"R Paus","year":"1999","unstructured":"Paus, R. & Cotsarelis, G. The biology of hair follicles. N. Engl. J. Med. 341, 491\u2013497 (1999).","journal-title":"N. Engl. J. Med."},{"key":"664_CR56","doi-asserted-by":"publisher","first-page":"R132","DOI":"10.1016\/j.cub.2008.12.005","volume":"19","author":"MR Schneider","year":"2009","unstructured":"Schneider, M. R., Schmidt-Ullrich, R. & Paus, R. The hair follicle as a dynamic miniorgan. Curr. Biol. 19, R132\u2013R142 (2009).","journal-title":"Curr. Biol."},{"key":"664_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0190-9622(91)70167-Z","volume":"25","author":"LC Sperling","year":"1991","unstructured":"Sperling, L. C. Hair anatomy for the clinician. J. Am. Acad. Dermatol. 25, 1\u201317 (1991).","journal-title":"J. Am. Acad. Dermatol."},{"key":"664_CR58","doi-asserted-by":"publisher","first-page":"893","DOI":"10.3390\/jcm12030893","volume":"12","author":"N Natarelli","year":"2023","unstructured":"Natarelli, N., Gahoonia, N. & Sivamani, R. K. Integrative and mechanistic approach to the hair growth cycle and hair loss. J. Clin. Med. 12, 893 (2023).","journal-title":"J. Clin. Med."},{"key":"664_CR59","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/bjd.14645","volume":"175","author":"M Bertolini","year":"2016","unstructured":"Bertolini, M. et al. Vasoactive intestinal peptide, whose receptor-mediated signalling may be defective in alopecia areata, provides protection from hair follicle immune privilege collapse. Br. J. Dermatol. 175, 531\u2013541 (2016).","journal-title":"Br. J. Dermatol."},{"key":"664_CR60","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.3390\/ijms23031038","volume":"23","author":"Y Minokawa","year":"2022","unstructured":"Minokawa, Y., Sawada, Y. & Nakamura, M. Lifestyle factors involved in the pathogenesis of alopecia areata. Int. J. Mol. Sci. 23, 1038 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"664_CR61","first-page":"43","volume":"8","author":"BE Prie","year":"2015","unstructured":"Prie, B. E. et al. Oxidative stress and alopecia areata. J. Med. Life 8, 43\u201346 (2015).","journal-title":"J. Med. Life"},{"key":"664_CR62","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/jdv.12932","volume":"30","author":"J Abou Rahal","year":"2016","unstructured":"Abou Rahal, J., Kurban, M., Kibbi, A. G. & Abbas, O. Plasmacytoid dendritic cells in alopecia areata: missing link? J. Eur. Acad. Dermatol. Venereol. 30, 119\u2013123 (2016).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"664_CR63","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.alit.2019.07.009","volume":"69","author":"T Ito","year":"2020","unstructured":"Ito, T. et al. Plasmacytoid dendritic cells as a possible key player to initiate alopecia areata in the C3H\/HeJ mouse. Allergol. Int. 69, 121\u2013131 (2020).","journal-title":"Allergol. Int."},{"key":"664_CR64","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/j.1365-2133.2010.09775.x","volume":"163","author":"M Ghoreishi","year":"2010","unstructured":"Ghoreishi, M., Martinka, M. & Dutz, J. P. Type 1 interferon signature in the scalp lesions of alopecia areata. Br. J. Dermatol. 163, 57\u201362 (2010).","journal-title":"Br. J. Dermatol."},{"key":"664_CR65","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1159\/000085580","volume":"211","author":"KJ McElwee","year":"2005","unstructured":"McElwee, K. J. et al. What can we learn from animal models of alopecia areata? Dermatology 211, 47\u201353 (2005).","journal-title":"Dermatology"},{"key":"664_CR66","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1586\/1744666X.2015.1085306","volume":"11","author":"H Guo","year":"2015","unstructured":"Guo, H., Cheng, Y., Shapiro, J. & McElwee, K. The role of lymphocytes in the development and treatment of alopecia areata. Expert Rev. Clin. Immunol. 11, 1335\u20131351 (2015).","journal-title":"Expert Rev. Clin. Immunol."},{"key":"664_CR67","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1038\/sj.jid.5701183","volume":"128","author":"T Ito","year":"2008","unstructured":"Ito, T. et al. Maintenance of hair follicle immune privilege is linked to prevention of NK cell attack. J. Invest. Dermatol. 128, 1196\u20131206 (2008).","journal-title":"J. Invest. Dermatol."},{"key":"664_CR68","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.immuni.2008.11.002","volume":"29","author":"CD Surh","year":"2008","unstructured":"Surh, C. D. & Sprent, J. Homeostasis of naive and memory T cells. Immunity 29, 848\u2013862 (2008).","journal-title":"Immunity"},{"key":"664_CR69","doi-asserted-by":"publisher","first-page":"3401","DOI":"10.1111\/all.16268","volume":"79","author":"M Kim","year":"2024","unstructured":"Kim, M. et al. Alopecia areata exhibits cutaneous and systemic OX40 activation across atopic backgrounds. Allergy 79, 3401\u20133414 (2024).","journal-title":"Allergy"},{"key":"664_CR70","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1111\/all.15561","volume":"78","author":"Y Renert-Yuval","year":"2023","unstructured":"Renert-Yuval, Y. et al. Scalp biomarkers during dupilumab treatment support Th2 pathway pathogenicity in alopecia areata. Allergy 78, 1047\u20131059 (2023).","journal-title":"Allergy"},{"key":"664_CR71","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jdermsci.2012.12.003","volume":"69","author":"T Ito","year":"2013","unstructured":"Ito, T. et al. CXCL10 produced from hair follicles induces Th1 and Tc1 cell infiltration in the acute phase of alopecia areata followed by sustained Tc1 accumulation in the chronic phase. J. Dermatol. Sci. 69, 140\u2013147 (2013).","journal-title":"J. Dermatol. Sci."},{"key":"664_CR72","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1159\/000486462","volume":"4","author":"E Kasumagic-Halilovic","year":"2018","unstructured":"Kasumagic-Halilovic, E., Cavaljuga, S., Ovcina-Kurtovic, N. & Zecevic, L. Serum levels of Interleukin-2 in patients with alopecia areata: relationship with clinical type and duration of the disease. Skin Appendage Disord. 4, 286\u2013290 (2018).","journal-title":"Skin Appendage Disord."},{"key":"664_CR73","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/bjd.12396","volume":"169","author":"MK Tembhre","year":"2013","unstructured":"Tembhre, M. K. & Sharma, V. K. T-helper and regulatory T-cell cytokines in the peripheral blood of patients with active alopecia areata. Br. J. Dermatol. 169, 543\u2013548 (2013).","journal-title":"Br. J. Dermatol."},{"key":"664_CR74","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/jocd.12970","volume":"19","author":"RK Gautam","year":"2020","unstructured":"Gautam, R. K. et al. The profile of cytokines (IL-2, IFN-gamma, IL-4, IL-10, IL-17A, and IL-23) in active alopecia areata. J. Cosmet. Dermatol. 19, 234\u2013240 (2020).","journal-title":"J. Cosmet. Dermatol."},{"key":"664_CR75","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1016\/j.jaci.2018.06.029","volume":"142","author":"T Song","year":"2018","unstructured":"Song, T. et al. An integrated model of alopecia areata biomarkers highlights both T(H)1 and T(H)2 upregulation. J. Allergy Clin. Immunol. 142, 1631\u20131634.e13 (2018).","journal-title":"J. Allergy Clin. Immunol."},{"key":"664_CR76","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1111\/all.14814","volume":"76","author":"JW Glickman","year":"2021","unstructured":"Glickman, J. W. et al. An integrated scalp and blood biomarker approach suggests the systemic nature of alopecia areata. Allergy 76, 3053\u20133065 (2021).","journal-title":"Allergy"},{"key":"664_CR77","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1111\/j.1468-3083.2006.02106.x","volume":"21","author":"L Manolache","year":"2007","unstructured":"Manolache, L. & Benea, V. Stress in patients with alopecia areata and vitiligo. J. Eur. Acad. Dermatol. Venereol. 21, 921\u2013928 (2007).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"664_CR78","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jaad.2020.06.047","volume":"85","author":"A Toussi","year":"2021","unstructured":"Toussi, A., Barton, V. R., Le, S. T., Agbai, O. N. & Kiuru, M. Psychosocial and psychiatric comorbidities and health-related quality of life in alopecia areata: a systematic review. J. Am. Acad. Dermatol. 85, 162\u2013175 (2021).","journal-title":"J. Am. Acad. Dermatol."},{"key":"664_CR79","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1038\/sj.jid.5700704","volume":"127","author":"F Siebenhaar","year":"2007","unstructured":"Siebenhaar, F. et al. Substance P as an immunomodulatory neuropeptide in a mouse model for autoimmune hair loss (alopecia areata). J. Invest. Dermatol. 127, 1489\u20131497 (2007).","journal-title":"J. Invest. Dermatol."},{"key":"664_CR80","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.2353\/ajpath.2007.061206","volume":"171","author":"EM Peters","year":"2007","unstructured":"Peters, E. M. et al. Probing the effects of stress mediators on the human hair follicle: substance P holds central position. Am. J. Pathol. 171, 1872\u20131886 (2007).","journal-title":"Am. J. Pathol."},{"key":"664_CR81","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1097\/DAD.0b013e318185a66e","volume":"31","author":"ED Cetin","year":"2009","unstructured":"Cetin, E. D., Savk, E., Uslu, M., Eskin, M. & Karul, A. Investigation of the inflammatory mechanisms in alopecia areata. Am. J. Dermatopathol. 31, 53\u201360 (2009).","journal-title":"Am. J. Dermatopathol."},{"key":"664_CR82","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/j.1600-0625.2011.01432.x","volume":"21","author":"M Kinori","year":"2012","unstructured":"Kinori, M. et al. Calcitonin gene-related peptide (CGRP) may award relative protection from interferon-gamma-induced collapse of human hair follicle immune privilege. Exp. Dermatol. 21, 223\u2013226 (2012).","journal-title":"Exp. Dermatol."},{"key":"664_CR83","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1016\/j.jaci.2021.10.036","volume":"149","author":"E Guttman-Yassky","year":"2022","unstructured":"Guttman-Yassky, E. et al. Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers. J. Allergy Clin. Immunol. 149, 1318\u20131328 (2022).","journal-title":"J. Allergy Clin. Immunol."},{"key":"664_CR84","doi-asserted-by":"publisher","first-page":"503587","DOI":"10.1155\/2010\/503587","volume":"2010","author":"EA Attia","year":"2010","unstructured":"Attia, E. A., El Shennawy, D. & Sefin, A. Serum interleukin-4 and total immunoglobulin E in nonatopic alopecia areata patients and HLA-DRB1 typing. Dermatol. Res. Pract. 2010, 503587 (2010).","journal-title":"Dermatol. Res. Pract."},{"key":"664_CR85","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1111\/all.13346","volume":"73","author":"T Czarnowicki","year":"2018","unstructured":"Czarnowicki, T. et al. Alopecia areata is characterized by expansion of circulating Th2\/Tc2\/Th22, within the skin-homing and systemic T-cell populations. Allergy 73, 713\u2013723 (2018).","journal-title":"Allergy"},{"key":"664_CR86","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jaad.2020.04.138","volume":"84","author":"JW Glickman","year":"2021","unstructured":"Glickman, J. W. et al. Cross-sectional study of blood biomarkers of patients with moderate to severe alopecia areata reveals systemic immune and cardiovascular biomarker dysregulation. J. Am. Acad. Dermatol. 84, 370\u2013380 (2021).","journal-title":"J. Am. Acad. Dermatol."},{"key":"664_CR87","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1111\/all.15071","volume":"77","author":"E Guttman-Yassky","year":"2022","unstructured":"Guttman-Yassky, E. et al. Phase 2a randomized clinical trial of dupilumab (anti-IL-4Ralpha) for alopecia areata patients. Allergy 77, 897\u2013906 (2022). The first clinical trial to use a targeted therapy demonstrating potential efficacy in alopecia areata.","journal-title":"Allergy"},{"key":"664_CR88","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/ced\/llac104","volume":"48","author":"S Holmes","year":"2023","unstructured":"Holmes, S. et al. Alopecia areata and risk of atopic and autoimmune conditions: population-based cohort study. Clin. Exp. Dermatol. 48, 325\u2013331 (2023).","journal-title":"Clin. Exp. Dermatol."},{"key":"664_CR89","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/pde.13387","volume":"35","author":"I Wohlmuth-Wieser","year":"2018","unstructured":"Wohlmuth-Wieser, I. et al. Childhood alopecia areata\u2014data from the National Alopecia Areata Registry. Pediatr. Dermatol. 35, 164\u2013169 (2018).","journal-title":"Pediatr. Dermatol."},{"key":"664_CR90","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/j.1365-2133.1990.tb01471.x","volume":"123","author":"HJ Michie","year":"1990","unstructured":"Michie, H. J., Jahoda, C. A., Oliver, R. F. & Poulton, T. A. Immunobiological studies on the alopecic (DEBR) rat. Br. J. Dermatol. 123, 557\u2013567 (1990).","journal-title":"Br. J. Dermatol."},{"key":"664_CR91","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1111\/j.1600-0625.2008.00773.x","volume":"17","author":"J Sun","year":"2008","unstructured":"Sun, J., Silva, K. A., McElwee, K. J., King, L. E. Jr & Sundberg, J. P. The C3H\/HeJ mouse and DEBR rat models for alopecia areata: review of preclinical drug screening approaches and results. Exp. Dermatol. 17, 793\u2013805 (2008).","journal-title":"Exp. Dermatol."},{"key":"664_CR92","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1046\/j.1523-1747.2003.12178.x","volume":"8","author":"L Tang","year":"2003","unstructured":"Tang, L., Cao, L., Pelech, S., Lui, H. & Shapiro, J. Cytokines and signal transduction pathways mediated by anthralin in alopecia areata-affected Dundee experimental balding rats. J. Investig. Dermatol. Symp. Proc. 8, 87\u201390 (2003).","journal-title":"J. Investig. Dermatol. Symp. Proc."},{"key":"664_CR93","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/sj.jidsp.5640219","volume":"4","author":"J Shapiro","year":"1999","unstructured":"Shapiro, J. et al. Alopecia areata-like hair loss in C3H\/HeJ mice and DEBR rats can be reversed using topical diphencyprone. J. Investig. Dermatol. Symp. Proc. 4, 239 (1999).","journal-title":"J. Investig. Dermatol. Symp. Proc."},{"key":"664_CR94","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/j.1365-2133.1997.tb03777.x","volume":"137","author":"KJ McElwee","year":"1997","unstructured":"McElwee, K. J., Rushton, D. H., Trachy, R. & Oliver, R. F. Topical FK506: a potent immunotherapy for alopecia areata? Studies using the Dundee experimental bald rat model. Br. J. Dermatol. 137, 491\u2013497 (1997).","journal-title":"Br. J. Dermatol."},{"key":"664_CR95","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/j.1365-2230.1995.tb02669.x","volume":"20","author":"RF Oliver","year":"1995","unstructured":"Oliver, R. F. & Lowe, J. G. Oral cyclosporin A restores hair growth in the DEBR rat model for alopecia areata. Clin. Exp. Dermatol. 20, 127\u2013131 (1995).","journal-title":"Clin. Exp. Dermatol."},{"key":"664_CR96","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1046\/j.1468-3083.2000.00097-14.x","volume":"14","author":"DD Verma","year":"2004","unstructured":"Verma, D. D. et al. Treatment of alopecia areata in the DEBR model using cyclosporin A lipid vesicles. Eur. J. Dermatol. 14, 332\u2013338 (2004).","journal-title":"Eur. J. Dermatol."},{"key":"664_CR97","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/1523-1747.ep12382416","volume":"102","author":"JP Sundberg","year":"1994","unstructured":"Sundberg, J. P., Cordy, W. R. & King, L. E. Jr. Alopecia areata in aging C3H\/HeJ mice. J. Invest. Dermatol. 102, 847\u2013856 (1994).","journal-title":"J. Invest. Dermatol."},{"key":"664_CR98","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1046\/j.1523-1747.1998.00380.x","volume":"111","author":"KJ McElwee","year":"1998","unstructured":"McElwee, K. J., Boggess, D., King, L. E. Jr. & Sundberg, J. P. Experimental induction of alopecia areata-like hair loss in C3H\/HeJ mice using full-thickness skin grafts. J. Invest. Dermatol. 111, 797\u2013803 (1998).","journal-title":"J. Invest. Dermatol."},{"key":"664_CR99","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1111\/j.0022-202X.2005.23692.x","volume":"124","author":"KJ McElwee","year":"2005","unstructured":"McElwee, K. J. et al. Transfer of CD8(+) cells induces localized hair loss whereas CD4(+)\/CD25(\u2212) cells promote systemic alopecia areata and CD4+\/CD25+ cells blockade disease onset in the C3H\/HeJ mouse model. J. Invest. Dermatol. 124, 947\u2013957 (2005).","journal-title":"J. Invest. Dermatol."},{"key":"664_CR100","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1126\/science.282.5396.2085","volume":"282","author":"A Poltorak","year":"1998","unstructured":"Poltorak, A. et al. Defective LPS signaling in C3H\/HeJ and C57BL\/10ScCr mice: mutations in Tlr4 gene. Science 282, 2085\u20132088 (1998).","journal-title":"Science"},{"key":"664_CR101","doi-asserted-by":"publisher","first-page":"477","DOI":"10.4049\/jimmunol.1100657","volume":"188","author":"R Alli","year":"2012","unstructured":"Alli, R., Nguyen, P., Boyd, K., Sundberg, J. P. & Geiger, T. L. A mouse model of clonal CD8+ T lymphocyte-mediated alopecia areata progressing to alopecia universalis. J. Immunol. 188, 477\u2013486 (2012).","journal-title":"J. Immunol."},{"key":"664_CR102","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/ng1297-393","volume":"17","author":"K Nagamine","year":"1997","unstructured":"Nagamine, K. et al. Positional cloning of the APECED gene. Nat. Genet. 17, 393\u2013398 (1997).","journal-title":"Nat. Genet."},{"key":"664_CR103","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/ng1297-399","volume":"17","author":"AC Finnish-German","year":"1997","unstructured":"Finnish-German, A. C. An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. Nat. Genet. 17, 399\u2013403 (1997).","journal-title":"Nat. Genet."},{"key":"664_CR104","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1126\/science.1075958","volume":"298","author":"MS Anderson","year":"2002","unstructured":"Anderson, M. S. et al. Projection of an immunological self shadow within the thymus by the aire protein. Science 298, 1395\u20131401 (2002).","journal-title":"Science"},{"key":"664_CR105","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1034\/j.1399-0039.2002.600604.x","volume":"60","author":"R Tazi-Ahnini","year":"2002","unstructured":"Tazi-Ahnini, R. et al. Role of the autoimmune regulator (AIRE) gene in alopecia areata: strong association of a potentially functional AIRE polymorphism with alopecia universalis. Tissue Antigens 60, 489\u2013495 (2002).","journal-title":"Tissue Antigens"},{"key":"664_CR106","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/j.1399-0039.2007.00992.x","volume":"71","author":"DA Wengraf","year":"2008","unstructured":"Wengraf, D. A. et al. Genetic analysis of autoimmune regulator haplotypes in alopecia areata. Tissue Antigens 71, 206\u2013212 (2008).","journal-title":"Tissue Antigens"},{"key":"664_CR107","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.jdcr.2018.03.004","volume":"4","author":"A Arousse","year":"2018","unstructured":"Arousse, A. et al. A novel AIRE gene mutation in a patient with autoimmune polyendocrinopathy candidiasis and ectodermal dystrophy revealed by alopecia areata. JAAD Case Rep. 4, 602\u2013605 (2018).","journal-title":"JAAD Case Rep."},{"key":"664_CR108","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1001\/archderm.1987.01660250050016","volume":"123","author":"A Gilhar","year":"1987","unstructured":"Gilhar, A. & Krueger, G. G. Hair growth in scalp grafts from patients with alopecia areata and alopecia universalis grafted onto nude mice. Arch. Dermatol. 123, 44\u201350 (1987).","journal-title":"Arch. Dermatol."},{"key":"664_CR109","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/j.1365-2133.1992.tb07815.x","volume":"126","author":"A Gilhar","year":"1992","unstructured":"Gilhar, A., Pillar, T., Assay, B. & David, M. Failure of passive transfer of serum from patients with alopecia areata and alopecia universalis to inhibit hair growth in transplants of human scalp skin grafted on to nude mice. Br. J. Dermatol. 126, 166\u2013171 (1992).","journal-title":"Br. J. Dermatol."},{"key":"664_CR110","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1172\/JCI551","volume":"101","author":"A Gilhar","year":"1998","unstructured":"Gilhar, A., Ullmann, Y., Berkutzki, T., Assy, B. & Kalish, R. S. Autoimmune hair loss (alopecia areata) transferred by T lymphocytes to human scalp explants on SCID mice. J. Clin. Invest. 101, 62\u201367 (1998). This experimental model confirms alopecia areata as a T cell-mediated disease.","journal-title":"J. Clin. Invest."},{"key":"664_CR111","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1001\/archderm.138.7.916","volume":"138","author":"A Gilhar","year":"2002","unstructured":"Gilhar, A. et al. Mediation of alopecia areata by cooperation between CD4+ and CD8+ T lymphocytes: transfer to human scalp explants on Prkdc(scid) mice. Arch. Dermatol. 138, 916\u2013922 (2002).","journal-title":"Arch. Dermatol."},{"key":"664_CR112","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1038\/jid.2012.365","volume":"133","author":"A Gilhar","year":"2013","unstructured":"Gilhar, A. et al. Autoimmune disease induction in a healthy human organ: a humanized mouse model of alopecia areata. J. Invest. Dermatol. 133, 844\u2013847 (2013).","journal-title":"J. Invest. Dermatol."},{"key":"664_CR113","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.80768","volume":"12","author":"R Laufer Britva","year":"2023","unstructured":"Laufer Britva, R. et al. Involvement of ILC1-like innate lymphocytes in human autoimmunity, lessons from alopecia areata. eLife 12, e80768 (2023).","journal-title":"eLife"},{"key":"664_CR114","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1111\/ajd.12227","volume":"57","author":"J Li","year":"2016","unstructured":"Li, J. & Sinclair, R. Clinical observations in alopecia areata: implications and hypotheses. Australas. J. Dermatol. 57, e29\u2013e31 (2016).","journal-title":"Australas. J. Dermatol."},{"key":"664_CR115","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/ajd.12941","volume":"60","author":"WC Cranwell","year":"2019","unstructured":"Cranwell, W. C. et al. Treatment of alopecia areata: an Australian expert consensus statement. Australas. J. Dermatol. 60, 163\u2013170 (2019).","journal-title":"Australas. J. Dermatol."},{"key":"664_CR116","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jaad.2006.05.008","volume":"55","author":"A Tosti","year":"2006","unstructured":"Tosti, A., Bellavista, S. & Iorizzo, M. Alopecia areata: a long term follow-up study of 191 patients. J. Am. Acad. Dermatol. 55, 438\u2013441 (2006).","journal-title":"J. Am. Acad. Dermatol."},{"key":"664_CR117","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jaad.2008.08.045","volume":"60","author":"BL Lew","year":"2009","unstructured":"Lew, B. L., Shin, M. K. & Sim, W. Y. Acute diffuse and total alopecia: a new subtype of alopecia areata with a favorable prognosis. J. Am. Acad. Dermatol. 60, 85\u201393 (2009).","journal-title":"J. Am. Acad. Dermatol."},{"key":"664_CR118","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1159\/000066435","volume":"205","author":"M Sato-Kawamura","year":"2002","unstructured":"Sato-Kawamura, M., Aiba, S. & Tagami, H. Acute diffuse and total alopecia of the female scalp. A new subtype of diffuse alopecia areata that has a favorable prognosis. Dermatology 205, 367\u2013373 (2002).","journal-title":"Dermatology"},{"key":"664_CR119","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/1346-8138.15306","volume":"47","author":"M Fukuyama","year":"2020","unstructured":"Fukuyama, M., Kinoshita-Ise, M., Sato, Y. & Ohyama, M. Elucidation of demographic, clinical and trichoscopic features for early diagnosis of self-healing acute diffuse and total alopecia. J. Dermatol. 47, 583\u2013591 (2020).","journal-title":"J. Dermatol."},{"key":"664_CR120","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1111\/ijd.13866","volume":"57","author":"K Chelidze","year":"2018","unstructured":"Chelidze, K. & Lipner, S. R. Nail changes in alopecia areata: an update and review. Int. J. Dermatol. 57, 776\u2013783 (2018).","journal-title":"Int. J. Dermatol."},{"key":"664_CR121","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.jaad.2017.10.048","volume":"79","author":"EA Olsen","year":"2018","unstructured":"Olsen, E. A. et al. Objective outcome measures: collecting meaningful data on alopecia areata. J. Am. Acad. Dermatol. 79, 470\u2013478.e3 (2018).","journal-title":"J. Am. Acad. Dermatol."},{"key":"664_CR122","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/j.1365-2133.1986.tb02825.x","volume":"114","author":"AG Messenger","year":"1986","unstructured":"Messenger, A. G., Slater, D. N. & Bleehen, S. S. Alopecia areata: alterations in the hair growth cycle and correlation with the follicular pathology. Br. J. Dermatol. 114, 337\u2013347 (1986).","journal-title":"Br. J. Dermatol."},{"key":"664_CR123","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1001\/archderm.139.12.1555","volume":"139","author":"DA Whiting","year":"2003","unstructured":"Whiting, D. A. Histopathologic features of alopecia areata: a new look. Arch. Dermatol. 139, 1555\u20131559 (2003).","journal-title":"Arch. Dermatol."},{"key":"664_CR124","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.jaad.2003.09.032","volume":"51","author":"EA Olsen","year":"2004","unstructured":"Olsen, E. A. et al. Alopecia areata investigational assessment guidelines\u2014Part II. National Alopecia Areata Foundation. J. Am. Acad. Dermatol. 51, 440\u2013447 (2004).","journal-title":"J. Am. Acad. Dermatol."},{"key":"664_CR125","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/bjd.18883","volume":"183","author":"KW Wyrwich","year":"2020","unstructured":"Wyrwich, K. W. et al. The Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trials. Br. J. Dermatol. 183, 702\u2013709 (2020).","journal-title":"Br. J. Dermatol."},{"key":"664_CR126","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.jaad.2021.08.043","volume":"86","author":"BA King","year":"2022","unstructured":"King, B. A. et al. Development of the alopecia areata scale for clinical use: results of an academic-industry collaborative effort. J. Am. Acad. Dermatol. 86, 359\u2013364 (2022). An important definition of alopecia areata disease severity that more comprehensively captures disease activity extending beyond only scalp involvement as measured by SALT.","journal-title":"J. Am. Acad. Dermatol."},{"key":"664_CR127","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1097\/MOP.0000000000000376","volume":"28","author":"L Castelo-Soccio","year":"2016","unstructured":"Castelo-Soccio, L. Diagnosis and management of hair loss in children. Curr. Opin. Pediatr. 28, 483\u2013489 (2016).","journal-title":"Curr. Opin. Pediatr."},{"key":"664_CR128","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/pde.14925","volume":"39","author":"AK Gupta","year":"2022","unstructured":"Gupta, A. K., Friedlander, S. F. & Simkovich, A. J. Tinea capitis: an update. Pediatr. Dermatol. 39, 167\u2013172 (2022).","journal-title":"Pediatr. Dermatol."},{"key":"664_CR129","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jaad.2020.03.004","volume":"83","author":"N Meah","year":"2020","unstructured":"Meah, N. et al. The alopecia Areata Consensus of Experts (ACE) study: results of an international expert opinion on treatments for alopecia areata. J. Am. Acad. Dermatol. 83, 123\u2013130 (2020).","journal-title":"J. Am. Acad. Dermatol."},{"key":"664_CR130","doi-asserted-by":"publisher","first-page":"e876","DOI":"10.1111\/1346-8138.17859","volume":"52","author":"M Ohyama","year":"2025","unstructured":"Ohyama, M. et al. Japanese Dermatological Association\u2019s clinical practice guidelines for alopecia areata 2024: a complete english translated version. J. Dermatol 52, e876\u2013e907 (2025).","journal-title":"J. Dermatol"},{"key":"664_CR131","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/jdv.19768","volume":"38","author":"L Rudnicka","year":"2024","unstructured":"Rudnicka, L. et al. European expert consensus statement on the systemic treatment of alopecia areata. J. Eur. Acad. Dermatol. Venereol. 38, 687\u2013694 (2024).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"664_CR132","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1001\/jamadermatol.2024.2734","volume":"160","author":"B King","year":"2024","unstructured":"King, B. et al. Baricitinib withdrawal and retreatment in patients with severe alopecia areata: the BRAVE-AA1 randomized clinical trial. JAMA Dermatol. 160, 1075\u20131081 (2024).","journal-title":"JAMA Dermatol."},{"key":"664_CR133","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/j.jid.2018.01.032","volume":"138","author":"A Jabbari","year":"2018","unstructured":"Jabbari, A. et al. An open-label pilot study to evaluate the efficacy of tofacitinib in moderate to severe patch-type alopecia areata, totalis, and universalis. J. Invest. Dermatol. 138, 1539\u20131545 (2018).","journal-title":"J. Invest. Dermatol."},{"key":"664_CR134","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.89790","volume":"1","author":"J Mackay-Wiggan","year":"2016","unstructured":"Mackay-Wiggan, J. et al. Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata. JCI Insight 1, e89790 (2016).","journal-title":"JCI Insight"},{"key":"664_CR135","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","volume":"374","author":"MC Genovese","year":"2016","unstructured":"Genovese, M. C. et al. Baricitinib in patients with refractory rheumatoid arthritis. N. Engl. J. Med. 374, 1243\u20131252 (2016).","journal-title":"N. Engl. J. Med."},{"key":"664_CR136","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1093\/bjd\/ljad096","volume":"189","author":"A Torrelo","year":"2023","unstructured":"Torrelo, A. et al. Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS). Br. J. Dermatol. 189, 23\u201332 (2023).","journal-title":"Br. J. Dermatol."},{"key":"664_CR137","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0140-6736(23)00921-2","volume":"402","author":"AV Ramanan","year":"2023","unstructured":"Ramanan, A. V. et al. Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial. Lancet 402, 555\u2013570 (2023).","journal-title":"Lancet"},{"key":"664_CR138","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jaad.2022.11.005","volume":"88","author":"K Ezzedine","year":"2023","unstructured":"Ezzedine, K. et al. Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial. J. Am. Acad. Dermatol. 88, 395\u2013403 (2023).","journal-title":"J. Am. Acad. Dermatol."},{"key":"664_CR139","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05470413 (2023)."},{"key":"664_CR140","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06012240 (2025)."},{"key":"664_CR141","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05051761 (2025)."},{"key":"664_CR142","doi-asserted-by":"publisher","first-page":"AB50","DOI":"10.1016\/j.jaad.2022.06.234","volume":"87","author":"NA Mesinkovska","year":"2022","unstructured":"Mesinkovska, N. A., Ito, T. & Senna, M. 34007 Efficacy and safety of baricitinib in adult patients with severe alopecia areata with or without an atopic background from 2 randomized, placebo-controlled, phase 3 trials. J. Am. Acad. Dermatol. 87, AB50 (2022).","journal-title":"J. Am. Acad. Dermatol."},{"key":"664_CR143","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1001\/jamadermatol.2015.4445","volume":"152","author":"BG Craiglow","year":"2016","unstructured":"Craiglow, B. G., Tavares, D. & King, B. A. Topical ruxolitinib for the treatment of alopecia universalis. JAMA Dermatol. 152, 490\u2013491 (2016).","journal-title":"JAMA Dermatol."},{"key":"664_CR144","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jaad.2017.03.024","volume":"77","author":"CB Bayart","year":"2017","unstructured":"Bayart, C. B., DeNiro, K. L., Brichta, L., Craiglow, B. G. & Sidbury, R. Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata. J. Am. Acad. Dermatol. 77, 167\u2013170 (2017).","journal-title":"J. Am. Acad. Dermatol."},{"key":"664_CR145","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.jaad.2019.10.016","volume":"82","author":"EA Olsen","year":"2020","unstructured":"Olsen, E. A., Kornacki, D., Sun, K. & Hordinsky, M. K. Ruxolitinib cream for the treatment of patients with alopecia areata: A 2-part, double-blind, randomized, vehicle-controlled phase 2 study. J. Am. Acad. Dermatol. 82, 412\u2013419 (2020).","journal-title":"J. Am. Acad. Dermatol."},{"key":"664_CR146","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00403-022-02336-0","volume":"315","author":"D Mikhaylov","year":"2023","unstructured":"Mikhaylov, D. et al. A phase 2a randomized vehicle-controlled multi-center study of the safety and efficacy of delgocitinib in subjects with moderate-to-severe alopecia areata. Arch. Dermatol. Res. 315, 181\u2013189 (2023).","journal-title":"Arch. Dermatol. Res."},{"key":"664_CR147","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jaad.2017.10.043","volume":"78","author":"LY Liu","year":"2018","unstructured":"Liu, L. Y., Craiglow, B. G. & King, B. A. Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients. J. Am. Acad. Dermatol. 78, 403\u2013404 e401 (2018).","journal-title":"J. Am. Acad. Dermatol."},{"key":"664_CR148","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jaad.2009.10.032","volume":"62","author":"A Alkhalifah","year":"2010","unstructured":"Alkhalifah, A., Alsantali, A., Wang, E., McElwee, K. J. & Shapiro, J. Alopecia areata update: part I. Clinical picture, histopathology, and pathogenesis. J. Am. Acad. Dermatol. 62, 177\u2013188 (2010). quiz 189\u2013190.","journal-title":"J. Am. Acad. Dermatol."},{"key":"664_CR149","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s40257-024-00869-w","volume":"25","author":"EL Simpson","year":"2024","unstructured":"Simpson, E. L. et al. Integrated safety update of abrocitinib in 3802 patients with moderate-to-severe atopic dermatitis: data from more than 5200 patient-years with up to 4 years of exposure. Am. J. Clin. Dermatol. 25, 639\u2013654 (2024).","journal-title":"Am. J. Clin. Dermatol."},{"key":"664_CR150","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg, S. R. et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N. Engl. J. Med. 386, 316\u2013326 (2022).","journal-title":"N. Engl. J. Med."},{"key":"664_CR151","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/jdv.19665","volume":"38","author":"M Senna","year":"2024","unstructured":"Senna, M. et al. Long-term efficacy and safety of baricitinib in patients with severe alopecia areata: 104-week results from BRAVE-AA1 and BRAVE-AA2. J. Eur. Acad. Dermatol. Venereol. 38, 583\u2013593 (2024).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"664_CR152","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40257-024-00846-3","volume":"25","author":"B King","year":"2024","unstructured":"King, B. et al. Integrated safety analysis of ritlecitinib, an oral JAK3\/TEC family kinase inhibitor, for the treatment of alopecia areata from the ALLEGRO clinical trial program. Am. J. Clin. Dermatol. 25, 299\u2013314 (2024).","journal-title":"Am. J. Clin. Dermatol."},{"key":"664_CR153","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1007\/s13555-023-00937-9","volume":"13","author":"P George","year":"2023","unstructured":"George, P. et al. Incidence rates of infections, malignancies, thromboembolism, and cardiovascular events in an alopecia areata cohort from a US claims database. Dermatol. Ther. 13, 1733\u20131746 (2023).","journal-title":"Dermatol. Ther."},{"key":"664_CR154","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.det.2012.08.010","volume":"31","author":"A Alkhalifah","year":"2013","unstructured":"Alkhalifah, A. Alopecia areata update. Dermatol. Clin. 31, 93\u2013108 (2013).","journal-title":"Dermatol. Clin."},{"key":"664_CR155","doi-asserted-by":"publisher","first-page":"248","DOI":"10.4103\/idoj.idoj_913_23","volume":"16","author":"F Begum","year":"2025","unstructured":"Begum, F., Mishra, S., Jena, A. K. & Panda, M. Comparison of safety and efficacy of topical mometasone 0.1% ointment, calcipotriol 0.005% ointment, and tacrolimus 0.1% ointment in patients with localized alopecia areata: a triple-arm randomized clinical study. Indian Dermatol. Online J. 16, 248\u2013257 (2025).","journal-title":"Indian Dermatol. Online J."},{"key":"664_CR156","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1080\/09546634.2020.1773384","volume":"33","author":"P Suchonwanit","year":"2022","unstructured":"Suchonwanit, P., Kositkuljorn, C., Mahasaksiri, T. & Leerunyakul, K. A comparison of the efficacy and tolerability of three corticosteroid treatment regimens in patients with alopecia areata. J. Dermatol. Treat. 33, 756\u2013761 (2022).","journal-title":"J. Dermatol. Treat."},{"key":"664_CR157","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1067\/mjd.2003.423","volume":"49","author":"A Tosti","year":"2003","unstructured":"Tosti, A., Piraccini, B. M., Pazzaglia, M. & Vincenzi, C. Clobetasol propionate 0.05% under occlusion in the treatment of alopecia totalis\/universalis. J. Am. Acad. Dermatol. 49, 96\u201398 (2003).","journal-title":"J. Am. Acad. Dermatol."},{"key":"664_CR158","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1111\/j.1468-3083.2006.01781.x","volume":"20","author":"A Tosti","year":"2006","unstructured":"Tosti, A., Iorizzo, M., Botta, G. L. & Milani, M. Efficacy and safety of a new clobetasol propionate 0.05% foam in alopecia areata: a randomized, double-blind placebo-controlled trial. J. Eur. Acad. Dermatol. Venereol. 20, 1243\u20131247 (2006).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"664_CR159","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1001\/archderm.136.10.1276","volume":"136","author":"S Charuwichitratana","year":"2000","unstructured":"Charuwichitratana, S., Wattanakrai, P. & Tanrattanakorn, S. Randomized double-blind placebo-controlled trial in the treatment of alopecia areata with 0.25% desoximetasone cream. Arch. Dermatol. 136, 1276\u20131277 (2000).","journal-title":"Arch. Dermatol."},{"key":"664_CR160","doi-asserted-by":"publisher","first-page":"149","DOI":"10.4103\/ijt.ijt_2_22","volume":"15","author":"SA Varghese","year":"2023","unstructured":"Varghese, S. A., Nair, S. S., George, A. E. & Yadev, I. Treatment response to diphenylcyclopropenone in patients with alopecia totalis\/universalis. Int. J. Trichol. 15, 149\u2013153 (2023).","journal-title":"Int. J. Trichol."},{"key":"664_CR161","doi-asserted-by":"publisher","first-page":"108186","DOI":"10.1016\/j.intimp.2021.108186","volume":"101","author":"A Al Bazzal","year":"2021","unstructured":"Al Bazzal, A. et al. A prospective comparative study of two regimens of diphenylcyclopropenone (DPCP) in the treatment of alopecia areata. Int. Immunopharmacol. 101, 108186 (2021).","journal-title":"Int. Immunopharmacol."},{"key":"664_CR162","doi-asserted-by":"publisher","first-page":"107971","DOI":"10.1016\/j.intimp.2021.107971","volume":"99","author":"N Ghandi","year":"2021","unstructured":"Ghandi, N. et al. A randomized trial of diphenylcyclopropenone (DPCP) combined with anthralin versus DPCP alone for treating moderate to severe alopecia areata. Int. Immunopharmacol. 99, 107971 (2021).","journal-title":"Int. Immunopharmacol."},{"key":"664_CR163","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1001\/jamadermatol.2018.2312","volume":"154","author":"S Lee","year":"2018","unstructured":"Lee, S., Kim, B. J., Lee, Y. B. & Lee, W. S. Hair regrowth outcomes of contact immunotherapy for patients with alopecia areata: a systematic review and meta-analysis. JAMA Dermatol. 154, 1145\u20131151 (2018).","journal-title":"JAMA Dermatol."},{"key":"664_CR164","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14447","volume":"33","author":"WMS Leong","year":"2020","unstructured":"Leong, W. M. S., Mok, Z. R. & Chandran, N. S. Limited efficacy of diphenylcyclopropenone in the treatment of alopecia areata: experience from a tertiary healthcare institution in Singapore. Dermatol. Ther. 33, e14447 (2020).","journal-title":"Dermatol. Ther."},{"key":"664_CR165","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1067\/mjd.2001.109309","volume":"44","author":"C Cotellessa","year":"2001","unstructured":"Cotellessa, C., Peris, K., Caracciolo, E., Mordenti, C. & Chimenti, S. The use of topical diphenylcyclopropenone for the treatment of extensive alopecia areata. J. Am. Acad. Dermatol. 44, 73\u201376 (2001).","journal-title":"J. Am. Acad. Dermatol."},{"key":"664_CR166","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/ced.12776","volume":"41","author":"RC Lamb","year":"2016","unstructured":"Lamb, R. C., Young, D. & Holmes, S. Retrospective review of diphencyprone in the treatment of alopecia areata. Clin. Exp. Dermatol. 41, 352\u2013358 (2016).","journal-title":"Clin. Exp. Dermatol."},{"key":"664_CR167","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/phpp.12596","volume":"36","author":"JH Lee","year":"2020","unstructured":"Lee, J. H. et al. Excimer laser\/light treatment of alopecia areata: a systematic review and meta-analyses. Photodermatol. Photoimmunol. Photomed. 36, 460\u2013469 (2020).","journal-title":"Photodermatol. Photoimmunol. Photomed."},{"key":"664_CR168","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s00403-019-01943-8","volume":"311","author":"MA El Taieb","year":"2019","unstructured":"El Taieb, M. A., Hegazy, E. M., Ibrahim, H. M., Osman, A. B. & Abualhamd, M. Topical calcipotriol vs narrowband ultraviolet B in treatment of alopecia areata: a randomized-controlled trial. Arch. Dermatol. Res. 311, 629\u2013636 (2019).","journal-title":"Arch. Dermatol. Res."},{"key":"664_CR169","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/j.1600-0781.2011.00612.x","volume":"27","author":"D Bayramgurler","year":"2011","unstructured":"Bayramgurler, D., Demirsoy, E. O., Akturk, A. S. & Kiran, R. Narrowband ultraviolet B phototherapy for alopecia areata. Photodermatol. Photoimmunol. Photomed. 27, 325\u2013327 (2011).","journal-title":"Photodermatol. Photoimmunol. Photomed."},{"key":"664_CR170","doi-asserted-by":"publisher","first-page":"569","DOI":"10.5021\/ad.2016.28.5.569","volume":"28","author":"YH Jang","year":"2016","unstructured":"Jang, Y. H. et al. A comparative study of oral cyclosporine and betamethasone minipulse therapy in the treatment of alopecia areata. Ann. Dermatol. 28, 569\u2013574 (2016).","journal-title":"Ann. Dermatol."},{"key":"664_CR171","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3109\/15569527.2013.839997","volume":"33","author":"G Acikgoz","year":"2014","unstructured":"Acikgoz, G., Caliskan, E., Tunca, M., Yeniay, Y. & Akar, A. The effect of oral cyclosporine in the treatment of severe alopecia areata. Cutan. Ocul. Toxicol. 33, 247\u2013252 (2014).","journal-title":"Cutan. Ocul. Toxicol."},{"key":"664_CR172","doi-asserted-by":"publisher","first-page":"101007","DOI":"10.1016\/j.vhri.2024.101007","volume":"43","author":"TF Tsai","year":"2024","unstructured":"Tsai, T. F. et al. Epidemiology, treatment patterns, and healthcare resource utilization study of patients with alopecia areata in Taiwan\u2019s National Health Insurance Research Database. Value Health Reg. Issues 43, 101007 (2024).","journal-title":"Value Health Reg. Issues"},{"key":"664_CR173","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1080\/09546634.2021.1886230","volume":"33","author":"H Husein-ElAhmed","year":"2022","unstructured":"Husein-ElAhmed, H. & Steinhoff, M. Efficacy and predictive factors of cyclosporine A in alopecia areata: a systematic review with meta-analysis. J. Dermatol. Treat. 33, 1643\u20131651 (2022).","journal-title":"J. Dermatol. Treat."},{"key":"664_CR174","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1001\/jamadermatol.2022.6687","volume":"159","author":"P Joly","year":"2023","unstructured":"Joly, P. et al. Efficacy of methotrexate alone vs methotrexate plus low-dose prednisone in patients with alopecia areata totalis or universalis: a 2-step double-blind randomized clinical trial. JAMA Dermatol. 159, 403\u2013410 (2023).","journal-title":"JAMA Dermatol."},{"key":"664_CR175","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1111\/jdv.16858","volume":"34","author":"VWY Lai","year":"2020","unstructured":"Lai, V. W. Y. & Sinclair, R. Utility of azathioprine, methotrexate and cyclosporine as steroid-sparing agents in chronic alopecia areata: a retrospective study of continuation rates in 138 patients. J. Eur. Acad. Dermatol. Venereol. 34, 2606\u20132612 (2020).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"664_CR176","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jaad.2004.10.873","volume":"52","author":"BR Kar","year":"2005","unstructured":"Kar, B. R., Handa, S., Dogra, S. & Kumar, B. Placebo-controlled oral pulse prednisolone therapy in alopecia areata. J. Am. Acad. Dermatol. 52, 287\u2013290 (2005).","journal-title":"J. Am. Acad. Dermatol."},{"key":"664_CR177","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.jaad.2015.12.026","volume":"74","author":"S Vano-Galvan","year":"2016","unstructured":"Vano-Galvan, S. et al. Pulse corticosteroid therapy with oral dexamethasone for the treatment of adult alopecia totalis and universalis. J. Am. Acad. Dermatol. 74, 1005\u20131007 (2016).","journal-title":"J. Am. Acad. Dermatol."},{"key":"664_CR178","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1111\/j.1346-8138.1999.tb02049.x","volume":"26","author":"VK Sharma","year":"1999","unstructured":"Sharma, V. K. & Gupta, S. Twice weekly 5\u2009mg dexamethasone oral pulse in the treatment of extensive alopecia areata. J. Dermatol. 26, 562\u2013565 (1999).","journal-title":"J. Dermatol."},{"key":"664_CR179","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S0190-9622(98)70009-X","volume":"39","author":"A Friedli","year":"1998","unstructured":"Friedli, A. et al. Pulse methylprednisolone therapy for severe alopecia areata: an open prospective study of 45 patients. J. Am. Acad. Dermatol. 39, 597\u2013602 (1998).","journal-title":"J. Am. Acad. Dermatol."},{"key":"664_CR180","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15806","volume":"35","author":"A Lobato-Berezo","year":"2022","unstructured":"Lobato-Berezo, A. et al. Mini pulse corticosteroid therapy with oral dexamethasone for moderate to severe alopecia areata: a multicentric study. Dermatol. Ther. 35, e15806 (2022).","journal-title":"Dermatol. Ther."},{"key":"664_CR181","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/S0190-9622(87)80003-8","volume":"16","author":"VC Fiedler-Weiss","year":"1987","unstructured":"Fiedler-Weiss, V. C. Topical minoxidil solution (1% and 5%) in the treatment of alopecia areata. J. Am. Acad. Dermatol. 16, 745\u2013748 (1987).","journal-title":"J. Am. Acad. Dermatol."},{"key":"664_CR182","doi-asserted-by":"publisher","first-page":"7712","DOI":"10.3390\/jcm13247712","volume":"13","author":"M Majewski","year":"2024","unstructured":"Majewski, M., Gardas, K., Waskiel-Burnat, A., Ordak, M. & Rudnicka, L. The role of minoxidil in treatment of alopecia areata: a systematic review and meta-analysis. J. Clin. Med. 13, 7712 (2024).","journal-title":"J. Clin. Med."},{"key":"664_CR183","doi-asserted-by":"publisher","first-page":"188","DOI":"10.5021\/ad.23.032","volume":"36","author":"SH Lee","year":"2024","unstructured":"Lee, S. H., Jung, S. W. & Lee, W. S. Alopecia areata and season of onset: a retrospective study of 492 cases. Ann. Dermatol. 36, 188\u2013190 (2024).","journal-title":"Ann. Dermatol."},{"key":"664_CR184","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.jaad.2018.06.029","volume":"79","author":"E Putterman","year":"2018","unstructured":"Putterman, E. & Castelo-Soccio, L. Seasonal patterns in alopecia areata, totalis, and universalis. J. Am. Acad. Dermatol. 79, 974\u2013975 (2018).","journal-title":"J. Am. Acad. Dermatol."},{"key":"664_CR185","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1346-8138.2009.00647.x","volume":"36","author":"S Inui","year":"2009","unstructured":"Inui, S., Nakajima, T., Toda, N. & Itami, S. Fexofenadine hydrochloride enhances the efficacy of contact immunotherapy for extensive alopecia areata: retrospective analysis of 121 cases. J. Dermatol. 36, 323\u2013327 (2009).","journal-title":"J. Dermatol."},{"key":"664_CR186","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.jaad.2020.06.1026","volume":"84","author":"YB Lee","year":"2021","unstructured":"Lee, Y. B. & Lee, W. S. Efficacy of antihistamines in combination with topical corticosteroid and superficial cryotherapy for treatment of alopecia areata: a retrospective cohort study. J. Am. Acad. Dermatol. 84, 1152\u20131154 (2021).","journal-title":"J. Am. Acad. Dermatol."},{"key":"664_CR187","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jdermsci.2010.03.009","volume":"58","author":"M Ohyama","year":"2010","unstructured":"Ohyama, M., Shimizu, A., Tanaka, K. & Amagai, M. Experimental evaluation of ebastine, a second-generation anti-histamine, as a supportive medication for alopecia areata. J. Dermatol. Sci. 58, 154\u2013157 (2010).","journal-title":"J. Dermatol. Sci."},{"key":"664_CR188","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05205070 (2022)."},{"key":"664_CR189","doi-asserted-by":"publisher","first-page":"eabd2712","DOI":"10.1126\/sciadv.abd2712","volume":"6","author":"N Patsoukis","year":"2020","unstructured":"Patsoukis, N., Wang, Q., Strauss, L. & Boussiotis, V. A. Revisiting the PD-1 pathway. Sci. Adv. 6, eabd2712 (2020).","journal-title":"Sci. Adv."},{"key":"664_CR190","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05368103 (2025)."},{"key":"664_CR191","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/j.0105-2896.2009.00867.x","volume":"234","author":"W Cao","year":"2010","unstructured":"Cao, W. & Bover, L. Signaling and ligand interaction of ILT7: receptor-mediated regulatory mechanisms for plasmacytoid dendritic cells. Immunol. Rev. 234, 163\u2013176 (2010).","journal-title":"Immunol. Rev."},{"key":"664_CR192","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03532958 (2022)."},{"key":"664_CR193","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1002\/jcph.1522","volume":"60","author":"PA Frohna","year":"2020","unstructured":"Frohna, P. A. et al. Results from a first-in-human study of BNZ-1, a selective multicytokine inhibitor targeting members of the common gamma (gammac) family of cytokines. J. Clin. Pharmacol. 60, 264\u2013273 (2020).","journal-title":"J. Clin. Pharmacol."},{"key":"664_CR194","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06444451 (2025)."},{"key":"664_CR195","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1093\/bjd\/ljad240","volume":"189","author":"S Weidinger","year":"2023","unstructured":"Weidinger, S. et al. Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial. Br. J. Dermatol. 189, 531\u2013539 (2023).","journal-title":"Br. J. Dermatol."},{"key":"664_CR196","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04556734 (2024)."},{"key":"664_CR197","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","volume":"401","author":"WJ Sandborn","year":"2023","unstructured":"Sandborn, W. J. et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. Lancet 401, 1159\u20131171 (2023).","journal-title":"Lancet"},{"key":"664_CR198","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06018428 (2025)."},{"key":"664_CR199","doi-asserted-by":"publisher","first-page":"2468312","DOI":"10.1080\/19420862.2025.2468312","volume":"17","author":"F Bick","year":"2025","unstructured":"Bick, F., Blanchetot, C., Lambrecht, B. N. & Schuijs, M. J. Targeting gammac family cytokines with biologics: current status and future prospects. MAbs 17, 2468312 (2025).","journal-title":"MAbs"},{"key":"664_CR200","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06340360 (2025)."},{"key":"664_CR201","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53384-1","volume":"15","author":"JI Silverberg","year":"2024","unstructured":"Silverberg, J. I. et al. The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials. Nat. Commun. 15, 9230 (2024).","journal-title":"Nat. Commun."},{"key":"664_CR202","unstructured":"Q32 Bio. Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program [Press release]. Q32 Bio https:\/\/ir.q32bio.com\/news-releases\/news-release-details\/q32-bio-provides-bempikibart-program-update-including-next-steps (10 December 2024)."},{"key":"664_CR203","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05866562 (2025)."},{"key":"664_CR204","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05551793 (2025)."},{"key":"664_CR205","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.jaad.2021.08.050","volume":"87","author":"NS Ali","year":"2022","unstructured":"Ali, N. S., Tollefson, M. M., Lohse, C. M. & Torgerson, R. R. Incidence and comorbidities of pediatric alopecia areata: a retrospective matched cohort study using the Rochester Epidemiology Project. J. Am. Acad. Dermatol. 87, 427\u2013429 (2022).","journal-title":"J. Am. Acad. Dermatol."},{"key":"664_CR206","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1111\/jdv.17187","volume":"35","author":"A Waskiel-Burnat","year":"2021","unstructured":"Waskiel-Burnat, A. et al. Therapeutic management in paediatric alopecia areata: a systematic review. J. Eur. Acad. Dermatol. Venereol. 35, 1299\u20131308 (2021).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"664_CR207","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1111\/jocd.14122","volume":"21","author":"N Altunisik","year":"2022","unstructured":"Altunisik, N., Ucuz, I. & Turkmen, D. Psychiatric basics of alopecia areata in pediatric patients: evaluation of emotion dysregulation, somatization, depression, and anxiety levels. J. Cosmet. Dermatol. 21, 770\u2013775 (2022).","journal-title":"J. Cosmet. Dermatol."},{"key":"664_CR208","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1111\/jocd.13807","volume":"20","author":"S Savas Erdogan","year":"2021","unstructured":"Savas Erdogan, S., Falay Gur, T. & Dogan, B. Anxiety and depression in pediatric patients with vitiligo and alopecia areata and their parents: a cross-sectional controlled study. J. Cosmet. Dermatol. 20, 2232\u20132239 (2021).","journal-title":"J. Cosmet. Dermatol."},{"key":"664_CR209","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1111\/jdv.12315","volume":"28","author":"O Bilgic","year":"2014","unstructured":"Bilgic, O. et al. Psychiatric symptomatology and health-related quality of life in children and adolescents with alopecia areata. J. Eur. Acad. Dermatol. Venereol. 28, 1463\u20131468 (2014).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"664_CR210","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.1111\/jdv.16727","volume":"34","author":"RZ Conic","year":"2020","unstructured":"Conic, R. Z. et al. Comorbidities in pediatric alopecia areata. J. Eur. Acad. Dermatol. Venereol. 34, 2898\u20132901 (2020).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"664_CR211","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14991","volume":"33","author":"JH Lim","year":"2024","unstructured":"Lim, J. H., Kwon, S. H., Sim, W. Y. & Lew, B. L. A clinical investigation of early-onset alopecia areata in children: onset earlier than 4 years of age might have a better short-term prognosis. Exp. Dermatol. 33, e14991 (2024).","journal-title":"Exp. Dermatol."},{"key":"664_CR212","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/j.1365-2230.1989.tb02604.x","volume":"14","author":"FB De Waard-van der Spek","year":"1989","unstructured":"De Waard-van der Spek, F. B., Oranje, A. P., De Raeymaecker, D. M. & Peereboom-Wynia, J. D. Juvenile versus maturity-onset alopecia areata\u2013a comparative retrospective clinical study. Clin. Exp. Dermatol. 14, 429\u2013433 (1989).","journal-title":"Clin. Exp. Dermatol."},{"key":"664_CR213","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1001\/jamadermatol.2013.5764","volume":"150","author":"P Lenane","year":"2014","unstructured":"Lenane, P. et al. Clobetasol propionate, 0.05%, vs hydrocortisone, 1%, for alopecia areata in children: a randomized clinical trial. JAMA Dermatol. 150, 47\u201350 (2014).","journal-title":"JAMA Dermatol."},{"key":"664_CR214","first-page":"419","volume":"10","author":"M Borchert","year":"2016","unstructured":"Borchert, M. et al. An evaluation of the safety and efficacy of bimatoprost for eyelash growth in pediatric subjects. Clin. Ophthalmol. 10, 419\u2013429 (2016).","journal-title":"Clin. Ophthalmol."},{"key":"664_CR215","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1111\/pde.13688","volume":"35","author":"K Sardana","year":"2018","unstructured":"Sardana, K., Gupta, A. & Gautam, R. K. Recalcitrant alopecia areata responsive to leflunomide and anthralin-Potentially undiscovered JAK\/STAT inhibitors? Pediatr. Dermatol. 35, 856\u2013858 (2018).","journal-title":"Pediatr. Dermatol."},{"key":"664_CR216","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1111\/pde.13703","volume":"35","author":"SZ Wu","year":"2018","unstructured":"Wu, S. Z., Wang, S., Ratnaparkhi, R. & Bergfeld, W. F. Treatment of pediatric alopecia areata with anthralin: a retrospective study of 37 patients. Pediatr. Dermatol. 35, 817\u2013820 (2018).","journal-title":"Pediatr. Dermatol."},{"key":"664_CR217","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/pde.13049","volume":"34","author":"M Ozdemir","year":"2017","unstructured":"Ozdemir, M. & Balevi, A. Bilateral half-head comparison of 1% anthralin ointment in children with alopecia areata. Pediatr. Dermatol. 34, 128\u2013132 (2017).","journal-title":"Pediatr. Dermatol."},{"key":"664_CR218","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/j.1525-1470.2010.01191.x","volume":"27","author":"D Torchia","year":"2010","unstructured":"Torchia, D. & Schachner, L. A. Bilateral treatment for alopecia areata. Pediatr. Dermatol. 27, 415\u2013416 (2010).","journal-title":"Pediatr. Dermatol."},{"key":"664_CR219","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.clindermatol.2015.09.005","volume":"33","author":"LJ Goldberg","year":"2015","unstructured":"Goldberg, L. J. & Castelo-Soccio, L. A. Alopecia: kids are not just little people. Clin. Dermatol. 33, 622\u2013630 (2015).","journal-title":"Clin. Dermatol."},{"key":"664_CR220","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.jaad.2018.02.031","volume":"78","author":"E Putterman","year":"2018","unstructured":"Putterman, E. & Castelo-Soccio, L. Topical 2% tofacitinib for children with alopecia areata, alopecia totalis, and alopecia universalis. J. Am. Acad. Dermatol. 78, 1207\u20131209.e1201 (2018).","journal-title":"J. Am. Acad. Dermatol."},{"key":"664_CR221","doi-asserted-by":"publisher","first-page":"378","DOI":"10.36849\/JDD.7782","volume":"23","author":"Y Tembunde","year":"2024","unstructured":"Tembunde, Y. & Kindred, C. Ruxolitinib 1.5% topical cream for the treatment of pediatric alopecia areata. J. Drugs Dermatol. 23, 378\u2013379 (2024).","journal-title":"J. Drugs Dermatol."},{"key":"664_CR222","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/j.1365-2133.2011.10383.x","volume":"165","author":"M Royer","year":"2011","unstructured":"Royer, M. et al. Efficacy and tolerability of methotrexate in severe childhood alopecia areata. Br. J. Dermatol. 165, 407\u2013410 (2011).","journal-title":"Br. J. Dermatol."},{"key":"664_CR223","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1159\/000351559","volume":"227","author":"R Friedland","year":"2013","unstructured":"Friedland, R., Tal, R., Lapidoth, M., Zvulunov, A. & Ben Amitai, D. Pulse corticosteroid therapy for alopecia areata in children: a retrospective study. Dermatology 227, 37\u201344 (2013).","journal-title":"Dermatology"},{"key":"664_CR224","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00403-024-03225-4","volume":"316","author":"E David","year":"2024","unstructured":"David, E. et al. Dupilumab induces hair regrowth in pediatric alopecia areata: a real-world, single-center observational study. Arch. Dermatol. Res. 316, 487 (2024).","journal-title":"Arch. Dermatol. Res."},{"key":"664_CR225","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1111\/pde.15691","volume":"41","author":"D Metko","year":"2024","unstructured":"Metko, D., Mehta, S. & Sibbald, C. Dupilumab for the treatment of alopecia areata in pediatric patients with atopic dermatitis: a scoping review. Pediatr. Dermatol. 41, 1123\u20131126 (2024).","journal-title":"Pediatr. Dermatol."},{"key":"664_CR226","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1111\/1346-8138.16364","volume":"49","author":"T Ito","year":"2022","unstructured":"Ito, T. et al. Health-related quality of life in patients with alopecia areata: results of a Japanese survey with norm-based comparisons. J. Dermatol. 49, 584\u2013593 (2022).","journal-title":"J. Dermatol."},{"key":"664_CR227","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1111\/jdv.13520","volume":"30","author":"S Jankovic","year":"2016","unstructured":"Jankovic, S. et al. Quality of life in patients with alopecia areata: a hospital-based cross-sectional study. J. Eur. Acad. Dermatol. Venereol. 30, 840\u2013846 (2016).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"664_CR228","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1080\/13548506.2014.894641","volume":"20","author":"S Qi","year":"2015","unstructured":"Qi, S., Xu, F., Sheng, Y. & Yang, Q. Assessing quality of life in alopecia areata patients in China. Psychol. Health Med. 20, 97\u2013102 (2015).","journal-title":"Psychol. Health Med."},{"key":"664_CR229","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ijwd.2017.07.001","volume":"4","author":"R Abedini","year":"2018","unstructured":"Abedini, R. et al. Quality of life in mild and severe alopecia areata patients. Int. J. Women\u2019s Dermatol. 4, 91\u201394 (2018).","journal-title":"Int. J. Women\u2019s Dermatol."},{"key":"664_CR230","doi-asserted-by":"publisher","first-page":"e97","DOI":"10.1016\/j.jaad.2010.11.042","volume":"66","author":"EE Reid","year":"2012","unstructured":"Reid, E. E. et al. Clinical severity does not reliably predict quality of life in women with alopecia areata, telogen effluvium, or androgenic alopecia. J. Am. Acad. Dermatol. 66, e97\u2013e102 (2012).","journal-title":"J. Am. Acad. Dermatol."},{"key":"664_CR231","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1159\/000182253","volume":"218","author":"T Nijsten","year":"2009","unstructured":"Nijsten, T., Sampogna, F. & Abeni, D. Categorization of Skindex-29 scores using mixture analysis. Dermatology 218, 151\u2013154 (2009).","journal-title":"Dermatology"},{"key":"664_CR232","doi-asserted-by":"publisher","first-page":"e276","DOI":"10.1111\/j.1468-3083.2012.04629.x","volume":"27","author":"G Fabbrocini","year":"2013","unstructured":"Fabbrocini, G. et al. Quality of life in alopecia areata: a disease-specific questionnaire. J. Eur. Acad. Dermatol. Venereol. 27, e276\u2013e281 (2013).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"664_CR233","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1016\/j.jisp.2017.10.009","volume":"19","author":"TR Mendoza","year":"2018","unstructured":"Mendoza, T. R., Osei, J. & Duvic, M. The utility and validity of the alopecia areata symptom impact scale in measuring disease-related symptoms and their effect on functioning. J. Investig. Dermatol. Symp. Proc. 19, S41\u2013S46 (2018).","journal-title":"J. Investig. Dermatol. Symp. Proc."},{"key":"664_CR234","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/bjd.21696","volume":"187","author":"Y Renert-Yuval","year":"2022","unstructured":"Renert-Yuval, Y. et al. Analysis of alopecia areata surveys suggests a threshold for improved patient-reported outcomes. Br. J. Dermatol. 187, 539\u2013547 (2022).","journal-title":"Br. J. Dermatol."},{"key":"664_CR235","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s13555-021-00512-0","volume":"11","author":"A Mostaghimi","year":"2021","unstructured":"Mostaghimi, A. et al. Patient perspectives of the social, emotional and functional impact of alopecia areata: a systematic literature review. Dermatol. Ther. 11, 867\u2013883 (2021).","journal-title":"Dermatol. Ther."},{"key":"664_CR236","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljaf318","author":"A Franz","year":"2025","unstructured":"Franz, A. et al. Quality of life, psychosocial difficulties and bullying in pediatric alopecia areata patients: a European Cross-Sectional study. Br. J. Dermatol. https:\/\/doi.org\/10.1093\/bjd\/ljaf318 (2025).","journal-title":"Br. J. Dermatol."},{"key":"664_CR237","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18848","author":"M Prendke","year":"2023","unstructured":"Prendke, M. et al. Quality of life in children and adolescents with alopecia areata-a systematic review. J. Eur. Acad. Dermatol. Venereol. https:\/\/doi.org\/10.1111\/jdv.18848 (2023).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"664_CR238","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1093\/bjd\/ljaf189","volume":"193","author":"E Christou","year":"2025","unstructured":"Christou, E. et al. Psychosocial burden and the impact of illness perceptions and stigma on quality of life, anxiety and depression in alopecia areata: results from the Alopecia\u2009+\u2009Me study. Br. J. Dermatol. 193, 458\u2013467 (2025).","journal-title":"Br. J. Dermatol."},{"key":"664_CR239","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/ajd.14311","volume":"65","author":"R Sinclair","year":"2024","unstructured":"Sinclair, R. et al. Health-related quality of life of adult and adolescent patients living with alopecia areata in Australia. Australas. J. Dermatol. 65, 451\u2013461 (2024).","journal-title":"Australas. J. Dermatol."},{"key":"664_CR240","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1111\/1346-8138.17786","volume":"52","author":"G Gauthier","year":"2025","unstructured":"Gauthier, G. et al. Perceived stigma among adults with alopecia areata in the United States. J. Dermatol. 52, 1185\u20131191 (2025).","journal-title":"J. Dermatol."},{"key":"664_CR241","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s00403-024-03513-z","volume":"317","author":"D Sharma","year":"2024","unstructured":"Sharma, D., Chau, C. A., O\u2019Hagan, R. & Ungar, B. Exploring health and social self-perceptions in U.S. adults with alopecia areata. Arch. Dermatol. Res. 317, 40 (2024).","journal-title":"Arch. Dermatol. Res."},{"key":"664_CR242","doi-asserted-by":"publisher","first-page":"e235","DOI":"10.1111\/ajd.14519","volume":"66","author":"R Sinclair","year":"2025","unstructured":"Sinclair, R. et al. Psychosocial and occupational burden on caregivers of adolescents with alopecia areata in Australia. Australas. J. Dermatol. 66, e235\u2013e240 (2025).","journal-title":"Australas. J. Dermatol."},{"key":"664_CR243","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1111\/jdv.20211","volume":"39","author":"MER Clemmesen","year":"2025","unstructured":"Clemmesen, M. E. R. et al. Psychosocial and mental impact of alopecia areata: analysis of the Danish Skin Cohort. J. Eur. Acad. Dermatol. Venereol. 39, 688\u2013697 (2025).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"664_CR244","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/j.jaad.2018.12.051","volume":"80","author":"E Putterman","year":"2019","unstructured":"Putterman, E. et al. Severity of disease and quality of life in parents of children with alopecia areata, totalis, and universalis: a prospective, cross-sectional study. J. Am. Acad. Dermatol. 80, 1389\u20131394 (2019).","journal-title":"J. Am. Acad. Dermatol."},{"key":"664_CR245","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1111\/ijd.17154","volume":"63","author":"SN Yucesoy","year":"2024","unstructured":"Yucesoy, S. N. et al. Evaluation of quality of life scores and family impact scales in pediatric patients with alopecia areata: a cross-sectional cohort study. Int. J. Dermatol. 63, 1414\u20131420 (2024).","journal-title":"Int. J. Dermatol."},{"key":"664_CR246","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s13555-025-01417-y","volume":"15","author":"KA Hanson","year":"2025","unstructured":"Hanson, K. A. et al. Comparison of dermatology life quality index scores in adults and adolescents with alopecia areata. Dermatol. Ther. 15, 1543\u20131553 (2025).","journal-title":"Dermatol. Ther."},{"key":"664_CR247","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1038\/jidsymp.2013.18","volume":"16","author":"Q Shi","year":"2013","unstructured":"Shi, Q. et al. Health-related quality of lLife (HRQoL) in alopecia areata patients-a secondary analysis of the National Alopecia Areata Registry Data. J. Investig. Dermatol. Symp. Proc. 16, S49\u2013S50 (2013).","journal-title":"J. Investig. Dermatol. Symp. Proc."},{"key":"664_CR248","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1007\/s13555-024-01208-x","volume":"14","author":"B Craiglow","year":"2024","unstructured":"Craiglow, B. et al. Improvement in measures of quality of life and symptoms of anxiety and depression in patients with severe alopecia areata achieving sustained scalp hair regrowth with baricitinib. Dermatol. Ther. 14, 1959\u20131968 (2024).","journal-title":"Dermatol. Ther."},{"key":"664_CR249","doi-asserted-by":"publisher","first-page":"2460577","DOI":"10.1080\/09546634.2025.2460577","volume":"36","author":"EH Law","year":"2025","unstructured":"Law, E. H. et al. Patient-reported outcome improvements following scalp hair regrowth among patients with alopecia areata: analysis of the ALLEGRO-2b\/3 trial. J. Dermatol. Treat. 36, 2460577 (2025).","journal-title":"J. Dermatol. Treat."},{"key":"664_CR250","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s12020-017-1280-y","volume":"57","author":"F Lolli","year":"2017","unstructured":"Lolli, F. et al. Androgenetic alopecia: a review. Endocrine 57, 9\u201317 (2017).","journal-title":"Endocrine"},{"key":"664_CR251","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s40257-019-00479-x","volume":"21","author":"M Starace","year":"2020","unstructured":"Starace, M., Orlando, G., Alessandrini, A. & Piraccini, B. M. Female androgenetic alopecia: an update on diagnosis and management. Am. J. Clin. Dermatol. 21, 69\u201384 (2020).","journal-title":"Am. J. Clin. Dermatol."},{"key":"664_CR252","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s40257-022-00740-w","volume":"24","author":"EA George","year":"2023","unstructured":"George, E. A., Matthews, C., Roche, F. C. & Taylor, S. C. Beyond the hot comb: updates in epidemiology, pathogenesis, and treatment of central centrifugal cicatricial alopecia from 2011 to 2021. Am. J. Clin. Dermatol. 24, 81\u201388 (2023).","journal-title":"Am. J. Clin. Dermatol."},{"key":"664_CR253","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/S0190-9622(86)70082-0","volume":"14","author":"IJ Frieden","year":"1986","unstructured":"Frieden, I. J. Aplasia cutis congenita: a clinical review and proposal for classification. J. Am. Acad. Dermatol. 14, 646\u2013660 (1986).","journal-title":"J. Am. Acad. Dermatol."},{"key":"664_CR254","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1001\/jamadermatol.2020.1698","volume":"156","author":"SA Elman","year":"2020","unstructured":"Elman, S. A. et al. Creation and validation of classification criteria for discoid lupus erythematosus. JAMA Dermatol. 156, 901\u2013906 (2020).","journal-title":"JAMA Dermatol."},{"key":"664_CR255","doi-asserted-by":"publisher","first-page":"1108623","DOI":"10.3389\/fmed.2023.1108623","volume":"10","author":"C Papara","year":"2023","unstructured":"Papara, C., De Luca, D. A., Bieber, K., Vorobyev, A. & Ludwig, R. J. Morphea: the 2023 update. Front. Med. 10, 1108623 (2023).","journal-title":"Front. Med."},{"key":"664_CR256","doi-asserted-by":"publisher","first-page":"4517","DOI":"10.3390\/jcm10194517","volume":"10","author":"E Ulc","year":"2021","unstructured":"Ulc, E. et al. Therapeutic and reconstructive management options in scleroderma (Morphea) en coup de sabre in children and adults. a systematic literature review. J. Clin. Med. 10, 4517 (2021).","journal-title":"J. Clin. Med."},{"key":"664_CR257","doi-asserted-by":"publisher","first-page":"890206","DOI":"10.3389\/fmed.2022.890206","volume":"9","author":"C Pomsoong","year":"2022","unstructured":"Pomsoong, C., Sukanjanapong, S., Ratanapokasatit, Y. & Suchonwanit, P. Epidemiological, clinical, and trichoscopic features of syphilitic alopecia: a retrospective analysis and systematic review. Front. Med. 9, 890206 (2022).","journal-title":"Front. Med."},{"key":"664_CR258","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/j.1600-0560.1991.tb00133.x","volume":"18","author":"JY Lee","year":"1991","unstructured":"Lee, J. Y. & Hsu, M. L. Alopecia syphilitica, a simulator of alopecia areata: histopathology and differential diagnosis. J. Cutan. Pathol. 18, 87\u201392 (1991).","journal-title":"J. Cutan. Pathol."},{"key":"664_CR259","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jdermsci.2021.01.007","volume":"101","author":"GO Chien Yin","year":"2021","unstructured":"Chien Yin, G. O., Siong-See, J. L. & Wang, E. C. E. Telogen effluvium - a review of the science and current obstacles. J. Dermatol. Sci. 101, 156\u2013163 (2021).","journal-title":"J. Dermatol. Sci."},{"key":"664_CR260","doi-asserted-by":"publisher","first-page":"112","DOI":"10.4103\/0378-6323.157456","volume":"82","author":"N Singh","year":"2016","unstructured":"Singh, N., Goyal, A., Thappa, D. M. & Rajesh, N. G. Congenital triangular alopecia: Is it always confined to fronto-temporal region? Indian J. Dermatol. Venereol. Leprol. 82, 112 (2016).","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"664_CR261","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.jaad.2016.02.1162","volume":"75","author":"A Haskin","year":"2016","unstructured":"Haskin, A. & Aguh, C. All hairstyles are not created equal: what the dermatologist needs to know about black hairstyling practices and the risk of traction alopecia (TA). J. Am. Acad. Dermatol. 75, 606\u2013611 (2016).","journal-title":"J. Am. Acad. Dermatol."},{"key":"664_CR262","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1093\/ced\/llad154","volume":"48","author":"E Balazic","year":"2023","unstructured":"Balazic, E. et al. Traction alopecia: assessing the presentation, management and outcomes in a diverse urban population. Clin. Exp. Dermatol. 48, 1030\u20131031 (2023).","journal-title":"Clin. Exp. Dermatol."},{"key":"664_CR263","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1525-1470.2011.01562.x","volume":"29","author":"MN Moody","year":"2012","unstructured":"Moody, M. N., Landau, J. M. & Goldberg, L. H. Nevus sebaceous revisited. Pediatr. Dermatol. 29, 15\u201323 (2012).","journal-title":"Pediatr. Dermatol."},{"key":"664_CR264","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s40257-015-0123-y","volume":"16","author":"P Patel","year":"2015","unstructured":"Patel, P., Malik, K. & Khachemoune, A. Sebaceous and Becker\u2019s nevus: overview of their presentation, pathogenesis, associations, and treatment. Am. J. Clin. Dermatol. 16, 197\u2013204 (2015).","journal-title":"Am. J. Clin. Dermatol."},{"key":"664_CR265","doi-asserted-by":"publisher","first-page":"17011","DOI":"10.1038\/nrdp.2017.11","volume":"3","author":"C Pratt","year":"2017","unstructured":"Pratt, C. et al. Alopecia areata. Nat. Rev. Dis. Primers 3, 17011 (2017).","journal-title":"Nat. Rev. Dis. Primers"}],"container-title":["Nature Reviews Disease Primers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41572-025-00664-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41572-025-00664-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41572-025-00664-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T08:02:56Z","timestamp":1762416176000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41572-025-00664-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":265,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["664"],"URL":"https:\/\/doi.org\/10.1038\/s41572-025-00664-9","relation":{},"ISSN":["2056-676X"],"issn-type":[{"value":"2056-676X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]},"assertion":[{"value":"15 October 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.U. is an employee of Mount Sinai and has received research funds (grants paid to the institution) from Bristol Myers Squibb, Incyte, Rapt Therapeutics, Pfizer and Sanofi. He is also a consultant for AbbVie, Arcutis Biotherapeutics, Bristol Myers Squibb, Botanix Pharmaceuticals, Castle Biosciences, Fresenius Kabi, Galderma, J&J, Leo Pharma, Lilly, Pfizer, Primus Pharmaceuticals, Sanofi and UCB. N.C.D. is a consultant for, performs clinical trials for and receives honoraria from Sanofi, Pfizer, Unilever, Direct Relief, L\u2019Or\u00e9al, Galderma, Avene and Tricholab. A.J. has received institutional grants from Arena Pharmaceuticals, InSilico Medicine and Pfizer and honoraria and\/or consultation fees from Pfizer. B.K. has served on advisory boards and\/or is a consultant and\/or is a clinical trial investigator and\/or is on a Data Monitoring Committee for AbbVie, AltruBio Inc., Almirall, Amgen, AnaptysBio, Apogee Therapeutics, Aquestive, Aslan Pharmaceuticals, Bristol Myers Squibb, Concert Pharmaceuticals Inc., Eli Lilly and Company, Equillium, Galderma, GSK, Horizon Therapeutics, Incyte Corp., Janssen Pharmaceuticals, LEO Pharma, Merck, Novartis, Otsuka\/Visterra Inc., Pfizer Inc., Q32 Bio Inc., Regeneron, Sanofi\u2013Genzyme, Soterios, Sun Pharmaceutical, Takeda, TWi Biotechnology Inc. and Ventyx Biosciences Inc. He has served on speaker bureaux for AbbVie, Incyte, Eli Lilly, Pfizer, Regeneron and Sanofi\u2013Genzyme. He is a scientific adviser for BiologicsMD. N.A.M. is a consultant, advisory board member and principal investigator for AbbVie, Lilly, Pfizer, Sun Pharma and Merck. She is also a member of the speakers\u2019 bureaux for Lilly and Pfizer. L.R. has given medical lectures for Leo Pharma, Novartis and UCB Pharma; participated in advisory board meetings of Leo Pharma, Novartis, Pfizer, Sanofi and UCB Pharma; and participated in the advisory board of the EMA. R.S. has been an investigator for and\/or provided professional services to AbbVie, Aerotek Scientific, Akeso Biopharma, Amgen, Arcutis, Arena Pharmaceuticals, Ascend Laboratories, AstraZeneca, Bayer Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Coherus BioSciences, Connect Biopharma, Cutanea, Dermira, Eli Lilly and Company, Galderma, GlaxoSmithKline, Janssen, LEO Pharma, MedImmune\u2013AstraZeneca, Merck Sharp & Dohme, Novartis, Oncobiologics, Pfizer, Regeneron, Reistone Biopharma, Roche, Samson Medical Technologies, Sanofi, Sun Pharma and UCB Pharma. E.G.-Y. has research grants from Boehringer Ingelheim, LEO Pharma, Pfizer, Cara Therapeutics, UCB, Kyowa Kirin, RAPT, Amgen, GSK, Incyte, Sanofi, Bristol Myers Squibb, ASLAN, Regeneron, AnaptysBio, Concert and Janssen; and has been a consultant for AbbVie, Almirall, Amgen, AnaptysBio, Apogee Therapeutics, Apollo Therapeutics, Artax Biopharma, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Cara Therapeutics, Centrexion Therapeutics, Connect Biopharm, Eli Lilly, Enveda Biosciences, Escient Pharmaceuticals, Fairmount Funds Management, Galderma, Gate Bio, Google Ventures, GSK Immunology, Horizon Therapeutics USA, Incyte, Inmagene, Janssen Biotech, Japan Tobacco, Jasper Therapeutics, Kyowa Kirin, LEO Pharma, Merck, Nektar Therapeutics, Novartis Pharmaceuticals, NUMAB Therapeutics, OrbiMed Advisors, OTSUKA Pfizer, Pharmaxis, Pioneering Medicine VII, Proteologix US, RAPT, Regeneron Pharmaceuticals, Ribon Therapeutics, Sanofi, SATO, Schr\u00f6dinger, Sun Pharma Advanced Research Company (SPARC), Teva Branded Pharmaceutical Products R&D and UCB. Y.R.-Y. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"77"}}